Overcoming cancer drug resistance


More about resistance

Cancer drug resistance



Financial reports

Financial Reports

Learn more about our unique first-in-class lead compound SCO-101

Watch the interview here: Part 1 / Part 2 / Part 3

Read more about SCO-101

Annual General Meeting

Scandion Oncology Annual General Meeting on May 6 at 14.00

Read more

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments

Read more